title: Chemoprevention of lung cancer.
abstract: OBJECTIVE
  Lung cancer is one of the major causes of cancer-related deaths. Grim mortality figures argue powerfully for new approaches to control this disease. Chemoprevention is the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer. The current article focuses on the field of lung cancer chemoprevention and recent advances. Lung cancer biology and general principles of prevention strategies are also described.
  
  
  RESULTS
  Trials in lung cancer chemoprevention have so far produced either neutral or harmful primary end point results whether in the primary, secondary and tertiary settings. The data suggest that lung cancer was not prevented by beta-carotene, alpha-tocopherol, retinal, retinyl palmitate, N-acetylcysteine, or isotretinoin in smokers. The results from the recently completed Canadian study of anethole dithiolethione in smokers with bronchial dysplasia as well secondary analyses of the phase III trials involving selenium and data from the US Intergroup NCI-91-0001 supporting treatment with isotretinoin in never and former smokers are hopeful and may help define new avenues of chemopreventive treatment after scientists and clinicians analyze the information generated.
  
  
  CONCLUSIONS
  The concept of chemoprevention in lung cancer is still in its infancy but one day may have a significant impact on the incidence and mortality of this leading cancer threat. An improved understanding of carcinogenesis and cancer prevention mechanisms will no doubt aid in the design of future clinical trials and in the validation of candidate agents as well as the development of new targets. Planned or ongoing trials currently are targeting important molecular markers of lung carcinogenesis and progression including cyclooxygenase-2, the ras-signaling pathway through farnesyl transferase inhibitors and the tyrosine kinase/epidermal growth factor receptor pathway. Until such studies are completed however, no drug or drug combination should be used for lung cancer prevention outside of a clinical study.
authors.affiliation: Sir Mortimer B. Davis-Jewish General Hospital, McGill University School of Medicine, Department of Oncology, Montreal, Quebec, Canada. vcohen@onc.jgh.mcgill.ca
authors.forename: Victor
authors.initials: V
authors.lastname: Cohen
authors.forename: Fadlo R
authors.initials: FR
authors.lastname: Khuri
mesh_terms: D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control*; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D012176:Retinoids / Q000627:therapeutic use
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D012176:Retinoids